Lazard Asset Management
PLX icon

Lazard Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Lazard Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$188K Buy
86,617
+15,224
+21% +$37.8K ﹤0.01% 1640
2025
Q4 		$129K Buy
+71,393
New +$146K ﹤0.01% 1719
2025
Q2 		– Sell
-797
Closed -$2K – 2479
2025
Q1 		$2K Sell
797
-458
-36% -$1.09K ﹤0.01% 2209
2024
Q4 		$2K Buy
+1,255
New +$1.77K ﹤0.01% 2188

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Lazard Asset Management's PLX Position: Q1 2026 in Review

Lazard Asset Management increased its Protalix BioTherapeutics (PLX) stake by 21% in Q1 2026, buying an estimated $37.8K and bringing the position to 86,617 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #1640.

Lazard Asset Management first reported a position in PLX in Q4 2024 and has held it in 4 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Lazard Asset Management held 86,617 shares of Protalix BioTherapeutics worth $188K as of Q1 2026.
  • Lazard Asset Management bought 15,224 Protalix BioTherapeutics shares in Q1 2026, an estimated $37.8K.
  • Protalix BioTherapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1640 holding.
  • Lazard Asset Management first reported a position in Protalix BioTherapeutics in Q4 2024 and has held it in 4 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.